Editorial board member, Dr Paolo A Ascierto, joins us at the Virtual 2020 ESMO Congress to discuss immunotherapy in BRAF-mutated metastatic melanoma and the major findings from the The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study.
Questions
- What is the rationale for the combination of targeted and immunotherapy in the treatment of BRAF-mutated metastatic melanoma? (0:18)
- Could you give us an overview of the aims and design of the SECOMBIT study? (0:57)
- What were the major findings of this study and what have they taught us about the optimal sequencing and timing of combination therapy? (3:20)
- Could you tell us a little about the ancillary study that will evaluate biomarkers? (5:27)
- What future studies are planned? (6:02)
Speaker Disclosures: Dr Paolo A Ascierto discloses the following: Advisory/Consultancy, Research grant/Funding (institution): Bristol Myers-Squibb; Advisory/Consultancy, Research grant/Funding (institution): Roche-Genentech; Advisory/Consultancy, Research grant/Funding (institution): Array; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Sharp & Dohme; Advisory/Consultancy: Novartis; Advisory/Consultancy: Merck Serono; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Incyte; Advisory/Consultancy: Newlink Genetics; Advisory/Consultancy: Genmab; Advisory/Consultancy: MedImmune; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Syndax; Advisory/Consultancy: SunPharma; Advisory/Consultancy: Sanofi; Advisory/Consultancy: Idera; Advisory/Consultancy: Ultimovacs; Advisory/Consultancy: Sandoz; Advisory/Consultancy: Immunocore; Advisory/Consultancy: 4SC; Advisory/Consultancy: Alkermes; Advisory/Consultancy: Italfarmaco; Advisory/Consultancy: Nektar; Advisory/Consultancy: Boehringer-Ingelheim.
Support: Interview and filming supported by Touch Medical Media Ltd. The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study was funded by Bristol Myers Squibb and Array Biopharma
Filmed in coverage of the Virtual 2020 ESMO Congress.
